17.08
+0.15(+0.89%)
Currency In USD
Address
55 Collins Street
Melbourne, VIC 3000
Australia
Phone
61 3 9639 6036
Website
Sector
Healthcare
Industry
Biotechnology
Employees
73
First IPO Date
January 20, 2010
| Name | Title | Pay | Year Born |
| Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director | 1.55M | 1957 |
| Dr. Paul J. Simmons BSc, Ph.D. | Scientific Advisor to the Chief Executive Officer | 0 | 1959 |
| Dr. Eric A. Rose M.D. | Chief Medical Officer & Executive Director | 825,260 | 1951 |
| Mr. James Michael O'Brien | Chief Financial Officer | 0 | 1966 |
| Mr. Justin Horst B.S. | Head of Manufacturing | 0 | N/A |
| Mr. Peter T. Howard B.Sc., L.L.B. | General Counsel & Corporate Executive | 0 | 1968 |
| Dr. Fiona See Ph.D. | Senior Vice President & Head of Translational Research | 0 | N/A |
| Mr. Marcelo Santoro | Chief Commercial Officer | 0 | N/A |
| Ms. Geraldine Storton B.Sc., M.B.A., MMS | Head of Regulatory Affairs & Quality Management | 0 | N/A |
| Ms. Niva Sivakumar B.Com., L.L.B. | Joint Company Secretary | 0 | N/A |
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.